Provided by Tiger Trade Technology Pte. Ltd.

CSPC PHARMA

8.855
-0.245-2.69%
Volume:109.50M
Turnover:965.59M
Market Cap:102.03B
PE:22.29
High:9.090
Open:8.900
Low:8.705
Close:9.100
52wk High:10.943
52wk Low:6.387
Shares:11.52B
HK Float Shares:11.52B
Volume Ratio:1.40
T/O Rate:0.95%
Dividend:0.34
Dividend Rate:3.81%
EPS(LYR):0.397
ROE:20.90%
ROA:10.70%
PB:2.32
PE(LYR):22.29
PS:2.79

Loading ...

CSPC Pharma's Clinical Data Presentations Could be Near-Term Share Catalysts

Dow Jones
·
20 mins ago

Movement Alert|CSPC PHARMA Falls 3.3% in Regular Trading, Pharma Sector Under Broad Selling Pressure Amid Global Risk-Off

Market Focus
·
4 hours ago

CSPC Pharma Gets Clinical Trial Nod in China for Solid Tumors Drug

MT Newswires Live
·
Yesterday

CSPC Pharmaceutical Says Rotigotine Long-Acting Injection Gets Clinical Trial Approval in China

Reuters
·
Yesterday

CSPC PHARMA Wins NMPA Approval to Start Clinical Trial for First Long-Acting Subcutaneous Rotigotine Injection

Bulletin Express
·
Yesterday

CSPC Pharma's Goserelin Extended-Release Injection Gets Clinical Trial Green Light in China

Stock News
·
Yesterday

CSPC Pharma Gains Chinese Clinical Trial Approval for Goserelin Extended-Release Injection

Stock News
·
Yesterday

CSPC Pharma Wins China Clinical Trial Clearance for Syh9102 Goserelin Injection

Reuters
·
Yesterday

CSPC Pharmaceutical - Goserelin Sustained-Release Injection (Syh9102 Injection) Obtains Clinical Trial Approval in China

THOMSON REUTERS
·
Yesterday

Movement Alert|CSPC PHARMA Falls 3.03% in Regular Trading, Global Market Selloff Drags Down Pharmaceutical Sector

Market Focus
·
Yesterday

CSPC Pharmaceutical Gets China Approval for Eye Drug Clinical Trials

MT Newswires Live
·
Sep 08

CSPC Wins China Clinical Trial Approval for Syh2083 Dry Eye Drops

Reuters
·
Sep 08

CSPC Pharmaceutical - Syh2083 Eye Drops Obtain Clinical Trial Approval in China

THOMSON REUTERS
·
Sep 08

CSPC Pharmaceutical Group Stock Falls 2.7% in Hong Kong, Underperforms Competitors

Dow Jones
·
Sep 08

Market Bets on BOJ Rate Hike While CICC's Merger Wins Regulatory Approval

Stock News
·
Sep 08

CSPC Pharma Begins Phase II Study of Influenza Drug in China

MT Newswires Live
·
Sep 07

Fourth Breakthrough Therapy Designation Granted to EGFR-Targeted ADC Developed by CSPC

Deep News
·
Sep 07

CSPC Pharma Initiates Phase II Trial of SYH2085 Tablet for Uncomplicated Influenza in Chinese Adults

Stock News
·
Sep 07

CSPC Pharmaceutical Group Stock Climbs 4.8% in Hong Kong

Dow Jones
·
Sep 03

Clinical Data Readouts Take Center Stage as Chinese Biotech Firms Surge; CSPC Pharma Climbs Over 4% While Huabao's HK Biotech ETF Holds Key Support

Deep News
·
Sep 03